All News

Can big pharma solve its fixed cost problem by going virtual? Not entirely, but drug companies can get more out of their CRO partners by treating them less like avatars and more like equals, according to conference-goers at a CBI event in The Triangle.

Big Pharma is quietly stepping up to provide critical supplies of essential medicines, other health equipment, and skilled local personnel to areas of the Philippines devastated by Typhoon Haiyan this month. Although industry operations in the Philippines appear largely intact, most companies are working through global humanitarian aid organizations due to the logistical challenges created by the collapse of infrastructure on the ground.

Oncology-market access doesn’t “just happen” anymore. As competition in the U.S. health-care market only continues to intensify, oncology-drug companies will need a good corporate strategy to ensure physician uptake and payer coverage of therapies.

At last week’s Partnering for Cures conference held in New York City, several expert panels discussed new angles of approaching solutions to disease, encouraging investment and mitigating inefficiencies in the delivery of medicines within the current healthcare system.

The future of healthcare centers on scale, population health and the value of care rather than the volume of care, according to thought leaders speaking at a leadership briefing in November in Akron, Ohio. But the political atmosphere also adds layers of complexity, they say.

FDA is proposing to revise its rules to permit generic drug manufacturers to initiate safety labeling changes, and not wait until the brand company takes that action.

Health plans that limit drug converge will encourage consumers to obtain medicines illegally, according to pharmacy experts.

Orphan drugs were given short shrift in PharmExec’s 2014 Pipeline Report, but a couple of pipeline candidates targeting small populations did make the list, and are expected to earn big dollars in the next few years.

In the early 1990’s, during the debate over the Clinton healthcare plan, I recall sitting in an interesting meeting at my pharma company headquarters.

Long awaited details have been announced in the Heads of Agreement for the latest Pharmaceutical Price Regulation Scheme (PPRS). It’s worth a read in full (and you can find it here) but some highlights are set out here.

A Twitter (TWTR) IPO is imminent and looks likely to cement the social network’s future - good news for pharma marketers that increasingly see the network as an important place to engage HCPs and the public.

Pharm Exec's two key features this month illustrate the strategic contradiction facing today's industry.

April might be – as T S Eliot suggested – the cruellest month, but for pharmaceuticals in Europe, October was certainly a contender to win an award as the busiest one.

The implosion of the Affordable Care Act’s vaunted healthcare.gov benefit enrollment process has obscured a far more critical issue for Big Pharma: how much leeway do companies have in promoting durable brand affiliations among the potentially millions of new patients with subsidized access to new medicines?

High prices, murky financial relations, and a reluctance to disclose clinical data are undermining public trust in industry and the research enterprise, writes Jill Wechsler.

Robert Hugin, Chairman of Celgene and PhRMA, talks about the challenges ahead for the industry organization

CPhI Worldwide and CPhI Pharma Evolution last week released Part II of the CPhI annual industry report, in which expert industry panel members share their views on trends that will drive growth and innovation across the pharmaceutical industry over the coming years and beyond.

Europe moved one step closer to a passport for physicians in earlier this month. The European Parliament gave its backing to creating a virtual professional qualifications card that will allow doctors, pharmacists, and other professionals to practice in another EU country.

Reporter Glenn Greenwald, who has been in the news recently for disseminating the whistle-blower and former CIA employee Edward Snowden’s information on the US’s mass surveillance program has left The Guardian where his initial articles appeared

When Warren Buffet was ten, he made his first trip to NYC. What did he want to do? “See the Stock Exchange,” he told a news reporter on TV yesterday.

Arena Pharmaceuticals’ and marketing partner Eisai’s Belviq – the first FDA-approved drug to treat obesity in over a decade – is making progress with payers and beefing up sales forces to target primary care physicians. DTC support began in September.

While buzz on Twitter will never outweigh critical data in a peer-reviewed publication, social media is becoming an important part of our industry’s dialogue. The oncology market is no exception, as insight gleaned from recent Twitter traffic and trends reveals.

Sophie Biernaux, VP & vaccine development leader, malaria and Joe Cohen, advisor malaria vaccine program, at GSK Vaccines at PhRMA?s Research and Hope Awards ceremonyon their innovative approach to vaccine development

A significant, though as yet not fully understood player in the launch of Obamacare is the pharmacy benefit manager (PBM) industry.

Advances in health information technology and new federal financial incentives are fueling rapid growth in the use of electronic medical record (EMR) systems

Like the Super Bowl, pharma companies are winning major congresses by using competitive conference techniques to generate brand buzz and corporate recognition.

Everything dies eventually. Print… Dead. Television… Dead… Even God… Dead. Well hold on to your hats, someone has said it, digital marketing is no more.

A new study shows the importance of intellectual property in stimulating jobs and productivity in the EU.

Compliance rules under the US Physician Payments Sunshine Act have been criticized for the excruciating level of detail demanded from individual company submissions.